Why Alpha Tau's TASE Listing Could Matter More Than Investors Think
Alpha Tau's TASE dual-listing lands on an exchange that returned ~52% in 2025, drew a ~5% stake from Bill Ackman, and channels passive index flows into new entrants — Palo Alto alone drew ~NIS 800M in ETF demand. At ~$1.2B, Alpha Tau clears TA-125 size on size alone.
When a company already trades on Nasdaq, filing for a second listing on another exchange might look like housekeeping. For Alpha Tau Medical Ltd. (Nasdaq: DRTS), it could be something more consequential. On August 10, the company filed to dual-list its shares on the Tel Aviv Stock Exchange, a move that CEO Uzi Sofer framed in personal terms: "After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home."
The question is not whether Alpha Tau needed a second listing. It is what could happen when a Nasdaq-listed oncology company with a market capitalization of approximately $1.2 billion becomes a locally traded security on an exchange that has quietly become one of the stronger-performing developed markets in the world.
Alpha Tau Is Entering a Very Different TASE
The Tel Aviv Stock Exchange that investors may remember is not the one Alpha Tau is joining. In 2025, the TA-35 gained approximately 52% and the TA-125 rose roughly 51%, compared with approximately 17-18% for the S&P 500. Institutional conviction in the exchange itself predates the rally: Pershing Square’s Bill Ackman and Neri Oxman disclosed a roughly 5% stake in the Tel Aviv Stock Exchange in early 2024, which Ackman described as “a royalty on the growth of Startup Nation.” TASE reported equity market capitalization of approximately NIS 2.97 trillion as of mid-2026, a 78% increase year over year, with 554 listed companies and average daily turnover of NIS 5.8 billion. In January 2026, TASE moved from a Sunday-through-Thursday trading week to Monday-through-Friday, aligning with Wall Street for the first time since the exchange was founded in 1953.
Behind the performance sits a less widely appreciated feature of Israel's financial system: Israeli institutional investors managed approximately NIS 3.3 trillion in assets at the end of Q1 2026. Israel's public financial asset portfolio stood at approximately NIS 7.25 trillion at the end of Q1 2026. A TASE listing means Alpha Tau shares would trade locally, through domestic clearing infrastructure, where local portfolio managers would encounter the stock through normal workflow rather than as a foreign security. In a market of 554 companies, a $1.2 billion name could become a substantially larger presence than it is on Nasdaq.
Index Inclusion Could Be What Makes This Listing Matter
TASE’s headline indices are constructed largely on market capitalization. The TA-125 tracks the 125 largest shares on the exchange; the TA-35 covers the top 35 by size; the TA-90 captures companies ranked roughly 36 through 125. TASE also operates a fast-track mechanism that can accelerate entry for newly eligible large names. Alpha Tau’s roughly $1.2 billion market capitalization translates to approximately ILS 4 billion. Against a TASE of 554 companies and total equity market cap near NIS 3 trillion, that size wouldplace Alpha Tau comfortably within TA-125 range on size alone, and likely within TA-90 range as well. Market cap is not the only inclusion criterion - free float, liquidity, and post-listing seasoning also matter, and nothing is guaranteed - but it is the primary hurdle, and Alpha Tau clears it by a wide margin.
That is what matters here: index inclusion creates structural, non-discretionary demand. Index-tracking funds and ETFs benchmarked to TA-125, TA-90, or TA-Biomed would need to build a position sized to the stock’s index weight, regardless of any active manager’s view - a mechanical inflow tied to the listing itself.
Israel's dual-listing framework makes the regulatory path straightforward. Nasdaq-listed companies can rely substantially on their existing SEC filings, meaning Alpha Tau can gain access to Israel's public markets without building an entirely separate reporting apparatus.
Palo Alto Networks Shows the Mechanism Is Real
Palo Alto Networks (Nasdaq: PANW) began trading on TASE in February 2026 and was approved for entry into both the TA-35 and TA-125 indices effective August 6, 2026, just six months later. Palo Alto alone was projected to generate approximately NIS 800 million (roughly $262 million) in ETF buying demand, according to Calcalist. Alpha Tau is a much smaller company and would not command the same index weight. But the mechanism is the same.
Alpha Tau is making this move from a position of strength. The company completed enrollment of 88 patients in its pivotal ReSTART trial, received Japanese marketing approval (Shonin) for Alpha DaRT(R), marking the platform's first regulatory approval outside Israel, holds two FDA Breakthrough Device Designations, and reported $104.8 million in cash as of June 30, 2026. In June, a strategic collaboration with Tolmar for U.S. prostate cancer commercialization included a $20 million equity investment at a 25% premium to market.
What a TASE listing potentially changes is the audience - a broader shareholder base, potential index eligibility and the passive demand that could accompany it, and another investor constituency reacting to future clinical and regulatory catalysts. Alpha Tau’s most important milestones will still come from the clinic. But the TASE listing could shape how many investors are watching when they land.
Read this Next >> Ford's $30,000 Gamble: Why the Fathom EV Truck Is the Most Important Bet in Detroit
Recent News Highlights from Alpha Tau
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Alpha Tau Medical Ltd. (the "Issuer") or a related party for coverage and awareness provided to the Issuer, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.
